latest update:
[TrialBase DB]

trial summary · NCT03258658

Safety and Feasibility Study of Autologous Engineered Urethral Constructs for the Treatment of Strictures

A Phase 1 Pilot Safety and Feasibility Study of Autologous Engineered Urethral

Trial record from the TrialBase DB dataset, status RECRUITING, condition Urologic Diseases, sponsored by Wake Forest University Health Sciences. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT03258658phase PHASE1enrollment 10start 2027-01

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

This is a Phase I clinical study to determine the safety and efficacy of using autologous, engineered urethral constructs for the treatment of urethral strictures in adult males. The proposed study design is a prospective non-randomized and uncontrolled single-center investigation. Autologous urothelial cells (UCs) and smooth muscle cells (SMCs), obtained from enrolled male subjects' bladder tissue samples, will be culture expanded in vitro and used to seed tubular PGA scaffolds to create autologous urethral constructs for the repair of urethral strictures.

Source record: https://clinicaltrials.gov/study/NCT03258658

Facts

registry idNCT03258658
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE1
study typeINTERVENTIONAL
lead conditionUrologic Diseases
sponsorWake Forest University Health Sciences
sponsor classOTHER
enrollment10
start date2027-01
primary completion2029-06
completion2029-06
results postednot reported

Conditions

  • Urologic Diseases
  • Male Urogenital Diseases
  • Urethral Stricture
  • Urethral Injury

Interventions

  • Autologous Engineered Urethral Construct

Countries

  • United States

Intervention types: BIOLOGICAL

Work with this record